Surgery Partners (SGRY) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Surgery Partners (SGRY) stock.

Latest Upgrades and Downgrades for Surgery Partners Stock

Date	Firm	Analyst	Action	Rating Change	Price Target
—	TD Cowen	Ryan Langston	PT Raise	Hold	$24→$25
—	RBC Capital	Ben Hendrix	PT Raise	Sector Perform	$24→$25
—	UBS	A.J. Rice	Downgrade	Buy→Neutral	$21→$24
—	StoneX	Bill Sutherland	Downgrade	Buy→Hold	—
—	RBC Capital	Ben Hendrix	Maintained	Outperform	$19
—	TD Cowen	Ryan Langston	Maintained	Buy	$19
—	JP Morgan	Benjamin Rossi	PT Raise	Neutral	$14→$15
—	TD Cowen	Ryan Langston	PT Raise	Buy	$17→$19
—	RBC Capital	Ben Hendrix	PT Cut	Outperform	$20→$19
—	Cantor Fitzgerald	Sarah James	Maintained	Overweight	$18
—	TD Cowen	Ryan Langston	PT Cut	Buy	$28→$20
—	UBS	A.J. Rice	PT Cut	Buy	$29→$21
—	Mizuho	Ann Hynes	PT Cut	Outperform	$19→$17
—	RBC Capital	Ben Hendrix	PT Cut	Outperform	$31→$20
—	Barclays	Andrew Mok	PT Cut	Equal-Weight	$18→$14
—	Mizuho	Ann Hynes	PT Cut	Outperform	$22→$19
—	JP Morgan	Benjamin Rossi	PT Cut	Neutral	$27→$20
—	Barclays	Andrew Mok	PT Cut	Equal-Weight	$24→$18
—	Mizuho	Ann Hynes	PT Cut	Outperform	$28→$22
—	UBS	A.J. Rice	PT Cut	Buy	$34→$29

Analyst Ratings News

PRO
TD Cowen Maintains Hold on Surgery Partners, Raises Price Target to $25

TD Cowen analyst Ryan Langston maintains Surgery Partners (NASDAQ:SGRY) with a Hold and raises the price target from $23.5 to $25.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Surgery Partners, Raises Price Target to $25

RBC Capital analyst Ben Hendrix maintains Surgery Partners (NASDAQ:SGRY) with a Sector Perform and raises the price target from $23.5 to $25.

Benzinga Newsdesk

PRO
UBS Downgrades Surgery Partners to Neutral, Raises Price Target to $23.5

UBS analyst A.J. Rice downgrades Surgery Partners (NASDAQ:SGRY) from Buy to Neutral and raises the price target from $21 to $23.5.

Benzinga Newsdesk

PRO
StoneX Downgrades Surgery Partners to Hold

StoneX analyst Bill Sutherland downgrades Surgery Partners (NASDAQ:SGRY) from Buy to Hold.

Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

RBC Capital analyst Ben Hendrix reiterates Surgery Partners (NASDAQ:SGRY) with a Outperform and maintains $19 price target.

Benzinga Newsdesk

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

TD Cowen analyst Ryan Langston reiterates Surgery Partners (NASDAQ:SGRY) with a Buy and maintains $19 price target.

Benzinga Newsdesk

Surgery Partners Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Surgery Partners (SGRY) Stock Price Target 2026

Latest Upgrades and Downgrades for Surgery Partners Stock

Surgery Partners (SGRY) Stock Price Target 2026

Latest Upgrades and Downgrades for Surgery Partners Stock

Analyst Ratings News

PRO
TD Cowen Maintains Hold on Surgery Partners, Raises Price Target to $25

PRO
RBC Capital Maintains Sector Perform on Surgery Partners, Raises Price Target to $25

PRO
UBS Downgrades Surgery Partners to Neutral, Raises Price Target to $23.5

PRO
StoneX Downgrades Surgery Partners to Hold

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PRO
TD Cowen Maintains Hold on Surgery Partners, Raises Price Target to $25

PRO
RBC Capital Maintains Sector Perform on Surgery Partners, Raises Price Target to $25

PRO
UBS Downgrades Surgery Partners to Neutral, Raises Price Target to $23.5

PRO
StoneX Downgrades Surgery Partners to Hold

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

Surgery Partners Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Surgery Partners (SGRY) Stock Price Target 2026

Latest Upgrades and Downgrades for Surgery Partners Stock

Surgery Partners (SGRY) Stock Price Target 2026

Latest Upgrades and Downgrades for Surgery Partners Stock

Analyst Ratings News

PROTD Cowen Maintains Hold on Surgery Partners, Raises Price Target to $25

PRORBC Capital Maintains Sector Perform on Surgery Partners, Raises Price Target to $25

PROUBS Downgrades Surgery Partners to Neutral, Raises Price Target to $23.5

PROStoneX Downgrades Surgery Partners to Hold

PRORBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PROTD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PROTD Cowen Maintains Hold on Surgery Partners, Raises Price Target to $25

PRORBC Capital Maintains Sector Perform on Surgery Partners, Raises Price Target to $25

PROUBS Downgrades Surgery Partners to Neutral, Raises Price Target to $23.5

PROStoneX Downgrades Surgery Partners to Hold

PRORBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PROTD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

PRO
TD Cowen Maintains Hold on Surgery Partners, Raises Price Target to $25

PRO
RBC Capital Maintains Sector Perform on Surgery Partners, Raises Price Target to $25

PRO
UBS Downgrades Surgery Partners to Neutral, Raises Price Target to $23.5

PRO
StoneX Downgrades Surgery Partners to Hold

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

PRO
TD Cowen Maintains Hold on Surgery Partners, Raises Price Target to $25

PRO
RBC Capital Maintains Sector Perform on Surgery Partners, Raises Price Target to $25

PRO
UBS Downgrades Surgery Partners to Neutral, Raises Price Target to $23.5

PRO
StoneX Downgrades Surgery Partners to Hold

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target